Post Bariatric Hypoglycemia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Post bariatric hypoglycemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Post Bariatric Hypoglycemia Today - Breaking & Trending Today

Vogenx Completes Dosing of Last Patient in Phase 2 Clinical Study of ...

Vogenx Completes Dosing of Last Patient in Phase 2 Clinical Study of . ....

United States , North Carolina , James Green , Vogenx Inc , News Network , Post Bariatric Hypoglycemia ,

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in.
-Today at 04:06 pm- MarketScreener ....

Aljanae Reynolds , David Apelian , Sylvia Wheeler , Progeroid Laminopathies , Company Annual Report On Form , Eiger Biopharmaceuticals Inc , Anges Inc , Eiger Biopharmaceuticals , Post Bariatric Hypoglycemia , Breakthrough Therapy , Congenital Hyperinsulinism , Pediatric Disease , Processing Deficient Progeroid , Distribution Agreement , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Consolidated Statements , Operations Financial ,

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; ext. ....

Aljanae Reynolds , Progeroid Laminopathies , Sylvia Wheeler , Bristol Myers Squibb , Thomas Dietz , Bluesphere Bio , David Apelian , Achillion Pharmaceuticals Inc , Prnewswire Eiger Biopharmaceuticals Inc , Schering Plough , Regulatory Affairs , Eiger Biopharmaceuticals Inc , Chief Executive Officer , Chief Operating Officer , Post Bariatric Hypoglycemia , Breakthrough Therapy , Pediatric Disease , Processing Deficient Progeroid , Based Regimens , Executive Medical Officer , Senior Clinical Advisor , Executive Vice President , Chief Medical Officer , Achillion Pharmaceuticals , Private Securities Litigation Reform Act , Quarterly Report ,

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
- Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021
- Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021
- Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm
- $3.6M U.S. Zokinvy® Net Sales in Q1 2021
News provided by
Share this article
Share this article
PALO ALTO, Calif., May 6, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its first quarter 2021 financial results and provided a business update.
The Phase 3 D-LIVR study is now 75% enrolled, and by year-end we expect to complete enrollment of this landmark global study advancing Lonafarnib, the only oral agent in development for HDV, setting the stage for Week 48 end ....

David Cory , Kim Sablich , Company Annual Report On Form , European Medicines Agency , Drug Administration , Eiger Biopharmaceuticals Inc , Program Updates , Eiger Biopharmaceuticals , Post Bariatric Hypoglycemia , Congenital Hyperinsulinism , Industry Veteran , Zokinvy Priority Review Voucher , Hepatitis Delta Virus , Hutchinson Gilford Progeria Syndrome , Marketing Authorization Application , Quarterly Report , Months Ended , Annual Report , Consolidated Statements , Operations Financial , டேவிட் கோரி , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , ஈகர் உயிர் மருந்துகள் இன்க் , ப்ரோக்ர்யாம் புதுப்பிப்புகள் , ஈகர் உயிர் மருந்துகள் , தொழில் மூத்த ,

Eiger BioPharmaceuticals : Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Global Phase 3 D-LIVR study enrollment completion planned in 2021
Peginterferon Lambda for HDV
Global Phase 3 LIMT-2 study initiation planned in 2021
Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
U.S. commercial launch in January 2021
EMA decision expected in 2H21
Lambda for COVID-19
Lancet Respiratory Medicine (Feld et al, 2021)
Considering strategic options to advance program
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Positive Phase 2 PREVENT study published in
JCEM (Craig et al, 2021)
Corporate
Pro-forma cash, cash equivalents and investments of $176.2M, including $128.8M as of December 31, 2020 plus $47.4M from net PRV sale proceeds received in January 2021, expected to fund planned operations through Q4 2023
Fourth Quarter and Full Year 2020 Financial Results ....

Progeroid Laminopathies , David Cory , Drug Administration , Program Product Updates , Company Annual Report On Form , Prnewswire Eiger Biopharmaceuticals Inc , European Medicines Agency , Eiger Biopharmaceuticals Inc , Access Program , Hepatitis Delta Virus , Processing Deficient Progeroid , Lancet Respiratory Medicine , Post Bariatric Hypoglycemia , Full Year , Priority Review Voucher , Hutchinson Gilford Progeria Syndrome , Marketing Authorization Application , Managed Access Program , Quarterly Report , Annual Report , Consolidated Statements , Operations Financial , Eiger Biopharmaceuticals , Inc Stock Exchange , Press Release , Of Eigr ,